CA3100020A1 - Mucus-penetrating peptides, delivery vehicles and methods of therapy - Google Patents
Mucus-penetrating peptides, delivery vehicles and methods of therapy Download PDFInfo
- Publication number
- CA3100020A1 CA3100020A1 CA3100020A CA3100020A CA3100020A1 CA 3100020 A1 CA3100020 A1 CA 3100020A1 CA 3100020 A CA3100020 A CA 3100020A CA 3100020 A CA3100020 A CA 3100020A CA 3100020 A1 CA3100020 A1 CA 3100020A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- mucus
- delivery vehicle
- composition
- penetrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 39
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 35
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 38
- 235000001014 amino acid Nutrition 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 20
- 239000003981 vehicle Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 239000002105 nanoparticle Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 10
- 150000002632 lipids Chemical group 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 235000018102 proteins Nutrition 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 7
- 235000018417 cysteine Nutrition 0.000 claims 6
- 108091005601 modified peptides Proteins 0.000 claims 6
- 238000002169 hydrotherapy Methods 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 201000001428 congenital diarrhea Diseases 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 150000001945 cysteines Chemical class 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 210000000110 microvilli Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 102100029790 Defensin-6 Human genes 0.000 claims 2
- 101000865479 Homo sapiens Defensin-6 Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000020603 familial colorectal cancer Diseases 0.000 claims 2
- 239000002479 lipoplex Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000000541 Defensins Human genes 0.000 claims 1
- 108010002069 Defensins Proteins 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671709P | 2018-05-15 | 2018-05-15 | |
| US62/671,709 | 2018-05-15 | ||
| PCT/US2019/032484 WO2019222400A2 (en) | 2018-05-15 | 2019-05-15 | Mucus-penetrating peptides, delivery vehicles and methods of therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3100020A1 true CA3100020A1 (en) | 2019-11-21 |
Family
ID=68540758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100020A Pending CA3100020A1 (en) | 2018-05-15 | 2019-05-15 | Mucus-penetrating peptides, delivery vehicles and methods of therapy |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210177982A1 (https=) |
| EP (1) | EP3796892A2 (https=) |
| JP (1) | JP2021523912A (https=) |
| CN (1) | CN112367974A (https=) |
| AU (1) | AU2019269590A1 (https=) |
| CA (1) | CA3100020A1 (https=) |
| WO (1) | WO2019222400A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230023615A1 (en) * | 2019-12-13 | 2023-01-26 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| US20230346700A1 (en) * | 2020-02-19 | 2023-11-02 | University Of Florida Research Foundation, Incorporated | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors |
| WO2022260678A1 (en) * | 2021-06-11 | 2022-12-15 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| EP4259099A1 (en) | 2020-12-14 | 2023-10-18 | Particella, Inc. | Biological delivery systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US176111A (en) | 1876-04-11 | Improvement in car-couplings | ||
| EP2253326B1 (en) * | 2008-02-28 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
| WO2012109363A2 (en) * | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| CA2863632C (en) * | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| AU2013256064B2 (en) * | 2012-05-03 | 2018-01-04 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR101669203B1 (ko) * | 2014-06-18 | 2016-10-25 | 한국과학기술연구원 | 신규 세포투과성 펩타이드 및 이의 용도 |
| WO2018013907A1 (en) * | 2016-07-15 | 2018-01-18 | Board Of Regents, The University Of Texas System | Mucus-penetrating peptides and screening assay |
| US11090391B2 (en) * | 2016-09-16 | 2021-08-17 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
-
2019
- 2019-05-15 WO PCT/US2019/032484 patent/WO2019222400A2/en not_active Ceased
- 2019-05-15 EP EP19804407.5A patent/EP3796892A2/en not_active Withdrawn
- 2019-05-15 CN CN201980045452.2A patent/CN112367974A/zh active Pending
- 2019-05-15 JP JP2020564152A patent/JP2021523912A/ja not_active Withdrawn
- 2019-05-15 AU AU2019269590A patent/AU2019269590A1/en not_active Abandoned
- 2019-05-15 CA CA3100020A patent/CA3100020A1/en active Pending
-
2020
- 2020-11-13 US US17/098,053 patent/US20210177982A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3796892A2 (en) | 2021-03-31 |
| JP2021523912A (ja) | 2021-09-09 |
| WO2019222400A3 (en) | 2020-02-13 |
| CN112367974A (zh) | 2021-02-12 |
| WO2019222400A2 (en) | 2019-11-21 |
| AU2019269590A1 (en) | 2020-12-03 |
| US20210177982A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020290516B2 (en) | Compositions and methods for biological delivery vehicles | |
| Mollé et al. | Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery | |
| US20210177982A1 (en) | Mucus-penetrating peptides, delivery vehicles and methods of therapy | |
| US20120258104A1 (en) | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes | |
| US20230023615A1 (en) | Compositions and methods for biological delivery vehicles | |
| US20190351071A1 (en) | Structures and methods for gene therapy | |
| JP6141517B2 (ja) | 脂肪細胞標的非ウイルス性遺伝子伝達体 | |
| Alexander-Bryant et al. | Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo | |
| WO2022260678A1 (en) | Compositions and methods for biological delivery vehicles | |
| US9976142B2 (en) | Targeting molecule and a use thereof | |
| Zhao et al. | Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics | |
| Hall et al. | Peptide/lipid-associated nucleic acids (PLANAs) as a multicomponent siRNA delivery system | |
| CA3205059A1 (en) | Biological delivery systems | |
| Geng et al. | Emerging landscape of cell-penetrating peptide-mediated organelle restoration and replacement | |
| Zhao | Zeng | |
| US12036282B2 (en) | Liposomal system for drug delivery | |
| US11890352B2 (en) | Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer | |
| Fu et al. | Virus-inspired lipopeptide-derived nucleic acid delivery to cartilage for osteoarthritis therapy | |
| CN117337330A (zh) | TMEM173 saRNA组合物和使用方法 |